

Anti-CD79b Antibody (Polatuzumab vedotin-piiq)

Introduction

Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) consisting of a monoclonal antibody against CD79b (a component of the B-cell receptor) and the anti-mitotic antibody cytotoxic agent monomethyl auristatin (MMAE). It is used to treat relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

Product parameters

Alternative Names	Polivy, RG7596, DCDS4501A
Target Accession	P40259
Target	CD79b
CAS number	1313206-42-6
Molecular Weight	150.53 kDa
Host	CHO
Reactivity	Human
Conjugation	MMAE
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	The drug-to-antibody ratio (DAR) of the Anti-CD79b Reference Antibody (Polatuzumab vedotin-piiq) is 3.8.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

